3M5L | A:1030-1178 | CRYSTAL STRUCTURE OF HCV NS3/4A PROTEASE IN COMPLEX WITH ITMN-191 |
3M5M | B:1030-1178; B:1030-1178 | AVOIDING DRUG RESISTANCE AGAINST HCV NS3/4A PROTEASE INHIBITORS |
3M5N | D:1030-1178; D:1030-1178; D:1030-1178; D:1030-1178 | CRYSTAL STRUCTURE OF HCV NS3/4A PROTEASE IN COMPLEX WITH N-TERMINAL PRODUCT 4B5A |
3M5O | B:1030-1178; B:1030-1178 | CRYSTAL STRUCTURE OF HCV NS3/4A PROTEASE IN COMPLEX WITH N-TERMINAL PRODUCT 5A5B |
3RC6 | A:1030-1178 | MOLECULAR MECHANISMS OF VIRAL AND HOST-CELL SUBSTRATE RECOGNITION BY HCV NS3/4A PROTEASE |
2OBQ | C:30-178; C:30-178 | DISCOVERY OF THE HCV NS3/4A PROTEASE INHIBITOR SCH503034. KEY STEPS IN STRUCTURE-BASED OPTIMIZATION |
2OC0 | C:30-178; C:30-178 | STRUCTURE OF NS3 COMPLEXED WITH A KETOAMIDE INHIBITOR SCH491762 |
2OC1 | C:30-178; C:30-178 | STRUCTURE OF THE HCV NS3/4A PROTEASE INHIBITOR CVS4819 |
2OC7 | C:30-178; C:30-178 | STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A PEPTIDE AND KETOAMIDE SCH571696 |
2OC8 | C:30-178; C:30-178 | STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A PEPTIDE AND KETOAMIDE SCH503034 |
3KNX | C:30-178; C:30-178 | HCV NS3 PROTEASE DOMAIN WITH P1-P3 MACROCYCLIC KETOAMIDE INHIBITOR |
3LON | C:30-178; C:30-178 | HCV NS3-4A PROTEASE DOMAIN WITH KETOAMIDE INHIBITOR NARLAPREVIR |
3LOX | C:30-178; C:30-178 | HCV NS3-4A PROTEASE DOMAIN WITH A KETOAMIDE INHIBITOR DERIVATIVE OF BOCEPREVIR BOUND |